Publication: Inpatient Prevalence, Expenditures, and Comorbidities of Sarcoidosis: Nationwide Inpatient Sample 2013–2014
Issued Date
2019-04-15
Resource Type
ISSN
14321750
03412040
03412040
Other identifier(s)
2-s2.0-85062040183
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Lung. Vol.197, No.2 (2019), 165-171
Suggested Citation
Patompong Ungprasert, Karn Wijarnpreecha, Wisit Cheungpasitporn, Charat Thongprayoon, Wuttiporn Manatsathit, Paul T. Kröner Inpatient Prevalence, Expenditures, and Comorbidities of Sarcoidosis: Nationwide Inpatient Sample 2013–2014. Lung. Vol.197, No.2 (2019), 165-171. doi:10.1007/s00408-019-00210-x Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51722
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Inpatient Prevalence, Expenditures, and Comorbidities of Sarcoidosis: Nationwide Inpatient Sample 2013–2014
Abstract
© 2019, Springer Science+Business Media, LLC, part of Springer Nature. Purpose: To investigate inpatient prevalence, expenditures, and comorbidities of hospitalized patients with sarcoidosis in the USA. Methods: Patients with sarcoidosis were identified within the Nationwide Inpatient Sample (NIS) database for the years 2013 and 2014 using the respective ICD-9 diagnostic code. Data on patient and hospital characteristics, comorbidities, total hospital costs, and total hospitalization charges were collected. A propensity-matched cohort of patients without sarcoidosis from the same database was created and used as comparators for the analysis of comorbidities. Results: A cohort of 78,055 patients with sarcoidosis was identified within the database, corresponding to an inpatient prevalence of 2.21 cases per 1000 admissions. Analysis of comorbidities found that patients with sarcoidosis had significantly higher odds of atrial fibrillation [adjusted odds ratio (aOR): 1.41, 95% CI 1.13–1.76, p < 0.01], conduction abnormalities [aOR: 2.04, 95% CI 1.45–2.89, p < 0.01], aortic valvulopathy [aOR: 1.78, 95% CI 1.30–2.44, p < 0.01], congestive heart failure [aOR: 1.23, 95% CI 1.04–1.45, p = 0.02], cardiomyopathy [aOR: 1.25, 95% CI 1.08–1.44, p < 0.01], deep venous thrombosis (aOR: 1.58, p < 0.01), pulmonary embolism (aOR: 1.70, p < 0.01), and osteoporosis (aOR: 1.81, p < 0.01), compared with propensity-matched patients without sarcoidosis. After adjusting for confounders, patients with sarcoidosis displayed a mean additional $1,250 (p = 0.24) in total hospital costs and a mean additional $27,205 (p < 0.01) in total hospitalization charges when compared to hospitalized patients without sarcoidosis. Conclusions: The inpatient prevalence of sarcoidosis was relatively high compared with its overall incidence. Hospitalization of patients with sarcoidosis was associated with a significantly higher total hospitalization charges compared to hospitalized patients without sarcoidosis. Patients with sarcoidosis have a higher risk of several cardiac comorbidities.